Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
SEC Accession No. 0001213900-25-014232
Filing Date
2025-02-14
Accepted
2025-02-14 16:00:06
Documents
1

Document Format Files

Seq Description Document Type Size
1 primary_doc.html SCHEDULE 13G/A  
1 primary_doc.xml SCHEDULE 13G/A 4673
  Complete submission text file 0001213900-25-014232.txt   6309
Mailing Address APP. 1, VIA GUIDINO 23 LUGANO-PARADISO V8 6900
Business Address
Tompkins Mark N. (Filed by) CIK: 0001455971 (see all company filings)

Type: SCHEDULE 13G/A

Mailing Address C/O LOMOND THERAPEUTICS HOLDINGS, INC. 8 THE GREEN STE 8490 DOVER DE 19901
Business Address C/O LOMOND THERAPEUTICS HOLDINGS, INC. 8 THE GREEN STE 8490 DOVER DE 19901 561 464 2841
Lomond Therapeutics Holdings, Inc. (Subject) CIK: 0001900520 (see all company filings)

EIN.: 872959575 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13G/A | Act: 34 | File No.: 005-93945 | Film No.: 25627894
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)